Capability profile

Universal blood-type conversion platform

Avivo develops enzyme-enabled methods intended to convert type-A blood cells and donor organs to universal type O, with public materials describing translational research and potential use in hospital, remote, emergency and trauma settings.

Request an introduction Add to Working List Download profileExplore Avivo Biomedical

How to read the record

Know what is sourced, assessed, current or still unknown.

Public-source factA released source supports the statement.
Our assessmentA person reviewed where the evidence may point.
Evidence strengthThe label reflects the quality and depth of public support.
Last reviewedThe date shows when the record was checked most recently.
Not yet verifiedMissing information stays visible instead of being invented.

Enzyme-enabled blood and organ compatibility platform

Capability overview

Core features

Blood-type conversion enzymes
Whole-blood conversion research
Organ-conversion research
Compatibility with existing clinical workflows

Defence and security uses

Emergency and trauma care
Remote care
Military medical support
Transplant medicine

What sets it apart

No source-supported differentiators are published yet.

Maturity

Maturity fields are not published because the reviewed sources do not support them.

Blood conversionEnzymologyTrauma careMedical biotechnologyUniversal donor

See the clearest reason to explore a conversation

Where this technology may help

Our assessmentLimited public evidence

Edge Data Processing

A portable, workflow-compatible clinical technology for urgent or remote care could be relevant to distributed support contexts; this is a derived assessment and is not a public procurement claim.

Supporting sourcesAvivo company and technology profile

This is a reviewed public-source assessment. It is not procurement eligibility, endorsement, customer interest, or classified demand.